CCL5 Protein (AA 24-91)

Catalog No. ABIN2666879

This Recombinant CCL5 protein is expressed in Escherichia coli (E. coli).

Quick Overview for CCL5 Protein (AA 24-91) (ABIN2666879)

Target: CCL5 (Chemokine (C-C Motif) Ligand 5 (CCL5))

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS)

Purity: > 97 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 24-91

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Bioactivity was measured by its ability to chemoattract Baf3-hCCR5 cells in a dose dependent manner.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is 0.1 M Glycine, 0.15 M NaCl buffer, pH 3.0.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: CCL5 (Chemokine (C-C Motif) Ligand 5 (CCL5))

Alternative Name: CCL5

Background: CCL5 is a CC chemokine that directs the migration of leukocytes in immune and inflammatory responses. Increased CCL5 expression has been associated with a wide range of inflammatory disorders and pathologies. It has been shown that CCL5 is highly expressed by breast tumor cells at primary tumor sites and is strongly associated with the progression of breast cancer. CCL5 may contribute to tumor progression by recruiting monocytes into tumor sites, and CCL5 can also stimulate the release of MMP, thereby promoting tumor cell migration. Some studies also show that CCL5 has pro-angiogenesis effects in vivo and in vitro. CCL5 oligomerization and binding to GAGs can induce angiogenic effects through its receptor CCR1 and CCR5. CCL5 is expressed in the early stages of many viral infections. It has been shown that CCL5 is protective against many viruses including influenza, RSV, HCMV, HCV, and HIV. CCL5 can inhibit HIV infection by competing with the virus for CCR5 binding. CCL5 also has been implicated in the development of asthma, artherosclerosis, and fibrosis.

Molecular Weight: The 68 amino acid recombinant protein has a predicted molecular mass of approximately 7.8 kDa. The DTT-reduced protein migrates at approximately 10 kDa and non-reduced protein migrates at approximately 11 kDa by SDS-PAGE. The predicted N-terminal amino ac

Pathways: Cellular Response to Molecule of Bacterial Origin, Regulation of G-Protein Coupled Receptor Protein Signaling, Smooth Muscle Cell Migration